OR WAIT 15 SECS
March 12. 2015.
Incepta Pharmaceuticals has introduced a version of Gilead's hepatitis C treatment, Sovaldi, at $10 a pill in Bangladesh, Bloomberg reports. The drug sells for $1,000 a pill in the United States.
Incepta doesn’t have a license from Gilead - Bangladesh is one country, along with Thailand, Malaysia and Morocco, where Sovaldi isn’t patented - but the company is marketing the treatment at about $900 for 12 weeks, the same price as Gilead is offering its branded version of the drug in India.